July 28, 2015 By Mark Terry , BioSpace.com Breaking News Staff Tarrytown, N.Y.-based Regeneron Pharmaceuticals announced today it had inked a global collaboration agreement with Paris-based Sanofi to develop and market cancer treatments utilizing programmed cell death protein 1 inhibitors. Sanofi is making an upfront payment of $640 million to Regeneron.
http://ift.tt/1IFQLOJ
No comments:
Post a Comment